Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00418

Target Information
NameCytochrome P450 3A4    
Type of targetSuccessful target    
SynonymsAlbendazole monooxygenase    
Albendazole sulfoxidase    
Cytochrome P450 3A3    
Nifedipine oxidase    
Quinine 3-monooxygenase    
Taurochenodeoxycholate 6-alpha-hydroxylase    
DiseaseHypothalamic-pituitary ACTH function    [1]
Drug(s)ClotrimazoleApprovedFungal infections[2][3]
BioChemical ClassOxidoreductases acting on paired donors    
EC NumberEC
PathwayDrug metabolism - cytochrome P450
Drug metabolism - other enzymes
Linoleic acid metabolism
Metabolic pathways
Metabolism of xenobiotics by cytochrome P450
Retinol metabolism
gamma-Hexachlorocyclohexane degradation
UniProt IDP08684
PDB Structure1TQN; 1W0E; 1W0F; 1W0G; 2J0D; 2V0M.    
Target ValidationClick to Find Target Validation Information.    
QSAR ModelClick to Find Target QSAR Model.    
Inhibitor (-)-clusin[4]
(-)-thujaplicatintrimethyl ether[4]
1- (3,4-DICHLOROPHENYL)-6-[8]
1- (4-Butoxy-phenyl)-1H-imidazole[9]
2,5-bis (4-hydroxybenzylidene)cyclopentanone[11]
2- (2-[12]
2- (4-Imidazol-1-yl-phenoxymethyl)-pyridine[9]
2-Fluoro-4-[5- (3-hydroxyphenyl)-2-thienyl]phenol[13]
2-[3- (4-Imidazol-1-yl-phenoxy)-propyl]-pyridine[9]
2-fluoro-5- (3-methylthiophen-2-yl)pyridine[5]
3,3- (1,3-Thiazole-2,5-diyl)diphenol[6]
3- (3-methylthiophen-2-yl)pyridine[5]
3- (5-[5]
3- (5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine[5]
3- (pyridin-3-yl)prop-2-yn-1-amine[5]
3-[3- (4-Imidazol-1-yl-phenoxy)-propyl]-pyridine[9]
3-[3- (4-Methoxybenzyl)naphthalen-2-yl]pyridine[14]
3-[5- (4-Hydroxyphenyl)-3-thienyl]phenol[6]
3-methoxy-5- (6-methoxynaphthalen-2-yl)pyridine[15]
4- (6-Methoxynaphthalen-2-yl)isoquinoline[15]
4-[2- (4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine[9]
4-[3- (4-Imidazol-1-yl-phenoxy)-propyl]-pyridine[9]
4-[5- (3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol[13]
4-[5- (3-Hydroxyphenyl)-3-thienyl]-2-methylphenol[13]
5- (2-phenethylpiperazin-1-yl)-1H-indazole[16]
5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime[17]
6- (3,4-DICHLOROPHENYL)-1-[1-[8]
6- (3-hydroxyphenyl)-2-naphthol[18]
6-Pyridin-3-yl-3,4-dihydronaphthalen-2 (1H)-one[19]
Methyl- (5-pyridin-3-yl-thiophen-2-yl)-amine[17]
SK&F-96365,   SK-96365[34]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. To Reference
Ref 2Oxidation of bilirubin in the brain-further characterization of a potentially protective mechanism. Mol Genet Metab. 1999 Nov;68(3):404-9. To Reference
Ref 3Effects of imidazole antimycotics on the liver microsomal cytochrome P450 isoforms in rats: comparison of in vitro and ex vivo studies. Eur J Drug Metab Pharmacokinet. 2000 Apr-Jun;25(2):121-6. To Reference
Ref 4J Nat Prod. 2005 Jan;68(1):64-8.Potent CYP3A4 inhibitory constituents of Piper cubeba. To Reference
Ref 5J Med Chem. 2006 Nov 30;49(24):6987-7001.Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. To Reference
Ref 6J Med Chem. 2008 Nov 13;51(21):6725-39. Epub 2008 Oct 15.Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). To Reference
Ref 7Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7. Epub 2009 Apr 24.Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. To Reference
Ref 8J Med Chem. 2010 Jul 8;53(13):4989-5001.6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. To Reference
Ref 9Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. To Reference
Ref 10Bioorg Med Chem Lett. 2001 Dec 3;11(23):2993-5.Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. To Reference
Ref 11Eur J Med Chem. 2008 Aug;43(8):1621-31. Epub 2007 Nov 17.Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. To Reference
Ref 12J Med Chem. 2010 May 13;53(9):3840-4.Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice. To Reference
Ref 13J Med Chem. 2009 Nov 12;52(21):6724-43.New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. To Reference
Ref 14J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. To Reference
Ref 15J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity. To Reference
Ref 16Bioorg. Med. Chem. Lett. 20(13):3941-3945 (2010) To Reference
Ref 17J Med Chem. 2005 Jan 13;48(1):224-39.5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. To Reference
Ref 18J Med Chem. 2008 Apr 10;51(7):2158-69. Epub 2008 Mar 7.Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. To Reference
Ref 19J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. To Reference
Ref 20Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. Epub 2006 Jul 28.Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. To Reference
Ref 21Bioorg Med Chem Lett. 2003 Nov 3;13(21):3643-5.Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4). To Reference
Ref 22Bioorg Med Chem. 2007 Jun 1;15(11):3684-91. Epub 2007 Mar 18.Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit. To Reference
Ref 23J Med Chem. 2008 Oct 9;51(19):5897-900. Epub 2008 Sep 3.Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. To Reference
Ref 24J Med Chem. 2008 Mar 27;51(6):1976-80. Epub 2008 Feb 21.Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). To Reference
Ref 25J Med Chem. 2008 Feb 28;51(4):1068-72. Epub 2008 Feb 5.Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. To Reference
Ref 26J Med Chem. 2010 Jan 14;53(1):18-36.Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. To Reference
Ref 27J Med Chem. 2010 Oct 14;53(19):7129-39.Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. To Reference
Ref 28J Med Chem. 2010 May 27;53(10):3973-4001.Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. To Reference
Ref 29Bioorg Med Chem Lett. 2008 Aug 1;18(15):4339-43. Epub 2008 Jun 28.Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. To Reference
Ref 30Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. To Reference
Ref 31J Nat Prod. 2007 Dec;70(12):1930-3. Epub 2007 Nov 10.Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria. To Reference
Ref 32J Med Chem. 2003 Jul 17;46(15):3230-44.Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. To Reference
Ref 33J Med Chem. 2004 Dec 2;47(25):6311-25.Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position. To Reference
Ref 34J Med Chem. 2008 Mar 27;51(6):1755-63. Epub 2008 Mar 1.Characterization of type II ligands in CYP2C9 and CYP3A4. To Reference
Ref 35J Nat Prod. 2004 Nov;67(11):1839-41.Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543